Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lucitanib + carboplatin + etoposide
- Development stage
- Unknown
- Lead developer
- Clovis Oncology
- Modality
- Small Molecules
- Administration
- Oral (lucitanib, Etoposide As Oral Formulation), Intravenous (lucitanib In Experimental Trials, Carboplatin, Etoposide)
01
Overview
A combination regimen of three drugs: **lucitanib**, **carboplatin**, and **etoposide**, used or considered for investigational therapy in cancer. Lucitanib is a small-molecule oral inhibitor of multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-3, and PDGFRα/β, showing activity in tumors with aberrations in FGF/FGFR pathways. Carboplatin and etoposide are standard chemotherapeutic agents commonly combined for the treatment of small cell lung cancer (SCLC), idiopathic interstitial pneumonia-complicated SCLC, and other select cancer types. This triplet combination is not established as a standard of care, but the combination of lucitanib and chemotherapy is under investigation for certain advanced cancers.[1][2][5][6]
- Other names
- AL3810 + carboplatin + etoposideLucitanib + Carboplatin + Etoposide
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)TOP2A (DNA topoisomerase II)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on lucitanib + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lucitanib + carboplatin + etoposide.